HGF and neoplasm: Specifically, we synthesized the optimal treatment strategy for a heterogeneous HGF treated tumor cell population consisting of 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R, T790M, and imposed a constraint that at most one switch could occur, as a starting point to simulate what might be most clinically feasible.